JRE #2461 - Robert F. Kennedy Jr. · Aired Feb 27, 2026
Claim summary · not a verbatim quotation
Aluminum adjuvants in vaccines accumulate in the brain and cause neurological damage.
The finding
What the evidence shows
Studies by Christopher Shaw (later retracted for data irregularities) alleged aluminum in vaccine adjuvants causes neurological damage. The mainstream scientific consensus is that aluminum adjuvants are safe at vaccine doses — the body excretes the vast majority within days. Infants receive far more aluminum through breast milk and infant formula than from vaccines. Research from the European Journal of Vaccines & Immunization and WHO SAGE Working Group on vaccine safety both concluded the evidence for adjuvant-related neurotoxicity is not established.
Read the supporting source · www.who.int ↗Quick answer & review status
Quick answer
Is it true that Aluminum adjuvants in vaccines accumulate in the brain and cause neurological damage?
Partly. The claim stretches what the evidence shows. Studies by Christopher Shaw (later retracted for data irregularities) alleged aluminum in vaccine adjuvants causes neurological damage. The mainstream scientific consensus is that aluminum adjuvants are safe at vaccine doses — the body excretes the vast majority within days. It was said on JRE #2461 - Robert F. Kennedy Jr., aired Feb 27, 2026, at 2:35:10. We haven't independently confirmed who said it. The supporting source is who.int, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.